 J Alzheimers Dis. Author manuscript; available in PMC 2010
August 17. Published in final edited form as: PMCID: PMC2922983
Oxidatively Modified Glyceraldehyde-3-Phosphate Dehydrogenase
(GAPDH) and Alzheimer Disease: Many Pathways to
Neurodegeneration   Recently, the oxidoreductase,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), has become a
subject of interest as more and more studies reveal a surfeit of
diverse GAPDH functions, extending beyond traditional aerobic
metabolism of glucose. As a result of multiple isoforms and
cellular locales, GAPDH is able to come in contact with a
variety of small molecules, proteins, membranes, etc. that play
important roles in normal and pathologic cell function.
Specifically, GAPDH has been shown to interact with
neurodegenerative disease-associated proteins, including the
β-amyloid precursor protein (AβPP). Studies from our laboratory
have shown significant inhibition of GAPDH dehydrogenase
activity in Alzheimer disease (AD) brain due to oxidative
modification. Altho